Inter J Phar: University of South Australia develops new prostate cancer drug with 40 per cent increase in efficacy

Introduction: Prostate cancer is one of the highest malignant tumors in older men and is known as the "silent killer"Prostate cancer is the 1st in the United States, with death rates second only to lung cancerIn China, the incidence of the disease is also growing rapidlyResearchers from the University of South Australia have developed a new drug for prostate cancer that has significantly improved its efficacy, giving new hope to patientsZytiga is often used to treat prostate cancer, but patients taking abitron must fast for two hours before taking the drug and then one hour after taking the drug to achieve the desired absorption effectAs you can imagine, this is very inconvenientIn general, only 10% of the dose of abitor can be absorbed by the body, the remaining 90% can not be dissolved, so can only be discharged as wasteBut a breakthrough research has led to a new formula for a drug called Abitron, which has improved its efficacy by 40 percent, giving new hope to prostate cancer patientsthe study was led by Dr Hayley Schultz of the Nanostructure and Drug Delivery Research Group, led by Professor Clive Prestidge of the University of South Australia's Cancer Institute and published in the International Journal of Pharmacy"Many drugs are water soluble, so when patients take these drugs, they enter the intestinebutt but don't dissolve, which means they have limited therapeutic effect," said Dr,of "Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica hybrids.
" "But their new formula dissolves high concentrations of acetic acid abitron in a specific fat and is wrapped in porous silica particles to form a powder that can be made into tablets or capsulesApplication scant scants can reduce the dose from 1000 mg per day to 700 mg without fastingresearchers conducted oral drug progenitorise studies of ratsThe dose of Abaaceate abitron (AbA) is 25 mg/kg Collect plasma samples and analyze drug content found that the silicondioxiy lipid mixture (SLH) with a saturation level of 90% lipid balanced solubility (Seq) increased the oral bioavailability of AbA by 31 times, and the oversaturation Ofia 150% Seq, 200% Seq and 250% Seq(super-SLH) increased the oral biological utilization of AbA by 1times and 10 times, respectively SLH (90% Seq) has a 1.43-fold increase in oral bioavailability compared to commercially available Abitron In the study of fat decomposition and oral drug pharmacokinetics, AbA, SLH and super-SLH had a reasonable in vitro-invivia correlation in the performance of the body The oil-based oral formulation they developed not only reduces the dose of the drug, but also has the potential to significantly reduce potential side effects such as joint swelling and diarrhea it's worth noting that this study first reported on the acetate abitron lipid-based formulation method, and the first reported on the oral pharmacokinetics of acetate Dr Hayley Schultz, lead researcher at the , said the new formula overcomes the disadvantages of fasting previously required for medication The use of fats to simulate the effects of drug food significantly increases the solubility and absorption rate of the drug, making it more effective and less invasive to patients, and ultimately providing better treatment for prostate cancer patients Professor Prestidge said: "Based on what we know about the drug's food effects, we hypothesize that with this technique, the absorption of the drug in the human body will be greatly improved Therefore, the research we do helps to develop commercial products that improve the lives of patients, which is priceless And the new formula is very flexible and can be applied to different drugs, so its potential to help all types of patients is exponential Ideally, a human clinical trial of this formula would take only two years "